Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutations”

880 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 880 results

Testing effectiveness (Phase 2)Looking for participantsNCT06563999
What this trial is testing

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Who this might be right for
Lung Cancer Stage IIIMutation
Sun Yat-sen University 120
Testing effectiveness (Phase 2)UnknownNCT04553887
What this trial is testing

Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 53
Testing effectiveness (Phase 2)Looking for participantsNCT07392658
What this trial is testing

Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.

Who this might be right for
Metastatic NSCLC - Non-Small Cell Lung Cancer
Fondazione Ricerca Traslazionale 33
Testing effectiveness (Phase 2)UnknownNCT02069418
What this trial is testing

Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient

Who this might be right for
Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer RecurrentNo EGFR Activating Mutation
University Hospital, Angers 80
Post-approval studies (Phase 4)UnknownNCT04864717
What this trial is testing

Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI

Who this might be right for
Acneiform EruptionsCancer, Treatment-Related
Lady Davis Institute 98
Testing effectiveness (Phase 2)Looking for participantsNCT06868485
What this trial is testing

Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Wayshine Biopharm, Inc. 40
Testing effectiveness (Phase 2)UnknownNCT03424759
What this trial is testing

Uncommon EGFR AZD9291

Who this might be right for
Non Small Cell Lung Cancer
Samsung Medical Center 37
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07343479
What this trial is testing

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Gene MutationsBrain Metastasis
Zhejiang Cancer Hospital 45
Large-scale testing (Phase 3)Active Not RecruitingNCT04765059
What this trial is testing

Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 98
Large-scale testing (Phase 3)UnknownNCT01405079
What this trial is testing

Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 222
Large-scale testing (Phase 3)Looking for participantsNCT07185997
What this trial is testing

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Who this might be right for
Non-Small-Cell Lung CancerMetastatic Non-Small-Cell Lung CancerAdvanced Non-Small-Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06363734
What this trial is testing

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Who this might be right for
Non-small Cell Lung CancerEGFR Activating MutationCell Cycle Deregulation+1 more
Tianjin Medical University Cancer Institute and Hospital 32
Not applicableNot Yet RecruitingNCT06520189
What this trial is testing

Value of F-18 FDG PET/CT for the Prediction of EGFR Mutation in Lung Cancer Patients

Who this might be right for
Lung Cancer
Assiut University 60
Large-scale testing (Phase 3)Study completedNCT00446225
What this trial is testing

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

Who this might be right for
Non-Small Cell Lung Cancer
Spanish Lung Cancer Group 174
Not applicableAvailableNCT06761976
What this trial is testing

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Who this might be right for
Advanced Non-small Cell Lung CancerCancer
Bayer
Testing effectiveness (Phase 2)UnknownNCT04974879
What this trial is testing

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Qingdao Central Hospital 20
Not applicableActive Not RecruitingNCT03908788
What this trial is testing

Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy

Who this might be right for
Metastatic Colorectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle 130
Early research (Phase 1)Study completedNCT03516214
What this trial is testing

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Who this might be right for
Bronchial Neoplasms
University of Cologne 18
Testing effectiveness (Phase 2)UnknownNCT06029816
What this trial is testing

Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations

Who this might be right for
NSCLC
Convalife (Shanghai) Co., Ltd. 42
Testing effectiveness (Phase 2)UnknownNCT05754736
What this trial is testing

Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.

Who this might be right for
Non-small Cell Lung Cancer
The Second Affiliated Hospital of Shandong First Medical University 50
Next Page
480